Inflammatory bowel disease: potential therapeutic strategies

O H Nielsen; B Vainer; S Bregenholt; Mogens Helweg Claesson; P D Bishop; I Kirman

Inflammatory bowel disease: potential therapeutic strategies

O H Nielsen, B Vainer, S Bregenholt, Mogens Helweg Claesson, P D Bishop, I Kirman

LUKKET: Institut for Immunologi og Mikrobiologi

8 Citationer (Scopus)

Abstract

This review deals with potential and possibly primary therapeutics that, through insight into the inflammatory cascade, result in more rational treatment principles replacing the classical therapy of inflammatory bowel disease (IBD), i.e. Crohn's disease (CD) and ulcerative colitis (UC). These new therapies might be useful for IBD patients, especially since the 'classical therapy' with agents like glucocorticoids, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin and methotrexate is often only moderately effective and may have important side-effects. Controlled trials of the novel agents mentioned in this review have not yet been performed, however.

Originalsprog	Engelsk
Tidsskrift	Cytokines Cellular and Molecular Therapy
Vol/bind	3
Udgave nummer	4
Sider (fra-til)	267-281
Antal sider	15
ISSN	1368-4736
Status	Udgivet - 1997

Citationsformater

@article{1532424074cb11dbbee902004c4f4f50,

title = "Inflammatory bowel disease: potential therapeutic strategies",

abstract = "This review deals with potential and possibly primary therapeutics that, through insight into the inflammatory cascade, result in more rational treatment principles replacing the classical therapy of inflammatory bowel disease (IBD), i.e. Crohn's disease (CD) and ulcerative colitis (UC). These new therapies might be useful for IBD patients, especially since the 'classical therapy' with agents like glucocorticoids, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin and methotrexate is often only moderately effective and may have important side-effects. Controlled trials of the novel agents mentioned in this review have not yet been performed, however.",

keywords = "Animals, Antibodies, Monoclonal, Antigens, CD4, Cell Adhesion Molecules, Cytokines, Factor XIII, Heparin, Humans, Inflammatory Bowel Diseases, Receptors, Cytokine",

author = "Nielsen, {O H} and B Vainer and S Bregenholt and Claesson, {Mogens Helweg} and Bishop, {P D} and I Kirman",

year = "1997",

language = "English",

volume = "3",

pages = "267--281",

journal = "Cytokines, Cellular and Molecular Therapy",

issn = "1368-4736",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Inflammatory bowel disease: potential therapeutic strategies

AU - Nielsen, O H

AU - Vainer, B

AU - Bregenholt, S

AU - Claesson, Mogens Helweg

AU - Bishop, P D

AU - Kirman, I

PY - 1997

Y1 - 1997

N2 - This review deals with potential and possibly primary therapeutics that, through insight into the inflammatory cascade, result in more rational treatment principles replacing the classical therapy of inflammatory bowel disease (IBD), i.e. Crohn's disease (CD) and ulcerative colitis (UC). These new therapies might be useful for IBD patients, especially since the 'classical therapy' with agents like glucocorticoids, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin and methotrexate is often only moderately effective and may have important side-effects. Controlled trials of the novel agents mentioned in this review have not yet been performed, however.

AB - This review deals with potential and possibly primary therapeutics that, through insight into the inflammatory cascade, result in more rational treatment principles replacing the classical therapy of inflammatory bowel disease (IBD), i.e. Crohn's disease (CD) and ulcerative colitis (UC). These new therapies might be useful for IBD patients, especially since the 'classical therapy' with agents like glucocorticoids, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporin and methotrexate is often only moderately effective and may have important side-effects. Controlled trials of the novel agents mentioned in this review have not yet been performed, however.

KW - Animals

KW - Antibodies, Monoclonal

KW - Antigens, CD4

KW - Cell Adhesion Molecules

KW - Cytokines

KW - Factor XIII

KW - Heparin

KW - Humans

KW - Inflammatory Bowel Diseases

KW - Receptors, Cytokine

M3 - Journal article

C2 - 9740355

SN - 1368-4736

VL - 3

SP - 267

EP - 281

JO - Cytokines, Cellular and Molecular Therapy

JF - Cytokines, Cellular and Molecular Therapy

IS - 4

ER -

Inflammatory bowel disease: potential therapeutic strategies

Abstract

Fingeraftryk

Citationsformater